

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org) on May 19, 2025

CD31 antibody

RRID:AB_2299349

Type: Antibody

Proper Citation

(Proteintech Cat# 11265-1-AP, RRID:AB_2299349)

Antibody Information

URL: http://antibodyregistry.org/AB_2299349

Proper Citation: (Proteintech Cat# 11265-1-AP, RRID:AB_2299349)

Target Antigen: CD31

Host Organism: rabbit

Clonality: polyclonal

Comments: Originating manufacturer of this product.
Applications: WB, IP, IHC, IF, FC, ELISA

Antibody Name: CD31 antibody

Description: This polyclonal targets CD31

Target Organism: monkey, rat, mouse, human

Antibody ID: AB_2299349

Vendor: Proteintech

Catalog Number: 11265-1-AP

Record Creation Time: 20231110T075854+0000

Record Last Update: 20241115T085049+0000

Ratings and Alerts

No rating or validation information has been found for CD31 antibody.

No alerts have been found for CD31 antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Shi M, et al. (2024) Genetic and microenvironmental evolution of colorectal liver metastases under chemotherapy. *Cell reports. Medicine*, 5(12), 101838.

Pechtimaldjian L, et al. (2024) Skin-iDISCO+: An optimized tissue-clearing and labeling protocol for morphometric analysis of human cutaneous vasculature. *STAR protocols*, 6(1), 103524.

Gao S, et al. (2024) Exercise training affects calcium ion transport by downregulating the CACNA2D1 protein to reduce hypertension-induced myocardial injury in mice. *iScience*, 27(4), 109351.

Zhang X, et al. (2023) IGFBP3 induced by the TGF- β /EGFRvIII transactivation contributes to the malignant phenotype of glioblastoma. *iScience*, 26(5), 106639.

Zhang H, et al. (2023) Venlafaxine antagonizes the noradrenaline-promoted colon cancer progression by inhibiting the norepinephrine transporter. *Cell death discovery*, 9(1), 152.

Zhai T, et al. (2023) Combination therapy with bevacizumab and a CCR2 inhibitor for human ovarian cancer: An in vivo validation study. *Cancer medicine*, 12(8), 9697.

Lv D, et al. (2023) Targeting phenylpyruvate restrains excessive NLRP3 inflammasome activation and pathological inflammation in diabetic wound healing. *Cell reports. Medicine*, 4(8), 101129.

Zhang K, et al. (2020) Nonclinical safety, tolerance and pharmacodynamics evaluation for meplazumab treating chloroquine-resistant *Plasmodium falciparum*. *Acta pharmaceutica Sinica. B*, 10(9), 1680.